Prognostic value of cancer stem cells, epithelial-mesenchymal transition and circulating tumor cells in lung cancer

Oncology Reports

Volumn 29, Issue 5, 2013, Pages 1763-1768

  Pirozzi, Giuseppe ^a   Tirino, V ^b   Camerlingo, R ^a   La Rocca, A ^a   Martucci, N ^a   Scognamiglio, G ^a   Franco, R ^a   Cantile, M ^a   Normanno, N ^a   Rocco, G ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Cancer stem cells; Circulating tumor cells; Epithelial mesenchymal transition; Prognosis

Indexed keywords

CD133 ANTIGEN; CYTOKERATIN; EPITHELIAL CELL ADHESION MOLECULE; THY 1 ANTIGEN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STEM CELL; CELL SUBPOPULATION; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; RECURRENCE RISK; RISK ASSESSMENT; TISSUE MICROARRAY;

ANTIGENS, CD; CARCINOMA, NON-SMALL-CELL LUNG; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; KERATINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; NEOPLASTIC STEM CELLS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; PULMONARY VEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84876240481     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2294     Document Type: Article

References (40)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005. (Pubitemid 40372904)
2. Jordan CT, Guzman ML and Noble M: Cancer stem cells. N Engl J Med 355: 1253-1261, 2006. (Pubitemid 44427449)
3. Visvader JE and Lindeman GJ: Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755-768, 2008.
4. Locke M, Heywood M, Fawell S and Mackenzie IC: Retention of intrinsic stem cell hierarchies in carcinoma-derived cell lines. Cancer Res 65: 8944-8950, 2005. (Pubitemid 41377385)
5. Singh SK, Clarke ID, Terasaki M, et al: Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-5828, 2003. (Pubitemid 37187480)
6. Ponti D, Costa A, Zaffaroni N, Pratesi G, et al: Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 65: 5506-5511, 2005. (Pubitemid 40911148)
7. Eramo A, Lotti F, Sette G, et al: Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15: 504-514, 2008. (Pubitemid 351267301)
8. Tirino V, Camerlingo R, Franco R, et al: The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur J Cardiothorac Surg 36: 446-453, 2009.
9. Chambers AF, Groom AC and MacDonald IC: Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2: 563-572, 2002. (Pubitemid 37328923)
10. Bonnomet A, Brysse A, Tachsidis A, et al: Epithelial-to-mesenchymal transitions and circulating tumor cells. J Mammary Gland Biol Neoplasia 15: 261-273, 2010.
11. Larue L and Bellacosa A: Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene 24: 7443-7454, 2005. (Pubitemid 41637984)
12. Pantel K and Brakenhoff RH: Dissecting the metastatic cascade. Nat Rev Cancer 4: 448-456, 2004. (Pubitemid 38745530)
13. Klein CA: Parallel progression of primary tumours and metastases. Nat Rev Cancer 9: 302-312, 2009.
14. Aguirre-Ghiso JA: Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 7: 834-846, 2007.
15. Pantel K, Alix-Panabières C and Riethdorf S: Cancer micrometastases. Nat Rev Clin Oncol 6: 339-351, 2009.
16. Franco R, Pirozzi G, Scala S, Cantile M, Scognamiglio G, Camerlingo R, Botti G and Rocco G: CXCL12-binding receptors expression in non-small cell lung cancer relates to tumoral microvascular density and CXCR4 positive circulating tumoral cells in lung draining venous blood. Eur J Cardiothorac Surg 41: 368-375, 2012.
17. Dick JE: Future prospects for animal models created by transplanting human haematopoietic cells into immune-deficient mice. Res Immunol 145: 380-384, 1994.
18. Ma S, Chan KW, Hu L, et al: Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132: 2542-2556, 2007. (Pubitemid 46890873)
19. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al: Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115, 2007. (Pubitemid 46067311)
20. Chen YC, Hsu HS, Chen YW, et al: Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS One3: e2637, 2008.
21. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, et al: Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA 106: 16281-16286, 2009.
22. Levina V, Marrangoni AM, DeMarco R, Gorelik E and Lokshin AE: Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One 3: e3077, 2008.
23. Basak SK, Veena MS, Oh S, Huang G, Srivatsan E, et al: The malignant pleural effusion as a model to investigate intratumoral heterogeneity in lung cancer. PLoS One 4: e5884, 2009.
24. Wu Y and Wu PY: CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev 18: 1127-1134, 2009.
25. Leung EL, Fiscus RR, Tung JW, et al: Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS One 5: e14062, 2010.
26. + cells is associated with poor prognosis in colon carcinoma patients with stage IIIB. J Transl Med 7: 56, 2009.
27. Xi HQ and Zhao P: Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma. J Clin Pathol 64: 498-503, 2011.
28. Artells R, Moreno I, Diaz T, et al: Tumour CD133 mRNA expression and clinical outcome in surgically resected colorectal cancer patients. Eur J Cancer 46: 642-649, 2010.
29. Horst D, Kriegl L, Engel J, et al: CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 99: 1285-1289, 2008.
30. Metellus P, Nanni-Metellus I, Delfino C, et al: Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution. Ann Surg Oncol 18: 2937-2945, 2011.
31. Sasaki A, Kamiyama T, Yokoo H, et al: Cytoplasmic expression of CD133 is an important risk factor for overall survival in hepatocellular carcinoma. Oncol Rep 24: 537-546, 2010.
32. Ishigami S, Ueno S, Arigami T, et al: Prognostic impact of CD133 expression in gastric carcinoma. Anticancer Res 30: 2453-2457, 2010.
33. Nakamura M, Kyo S, Zhang B, et al: Prognostic impact of CD133 expression as a tumor-initiating cell marker in endometrial cancer. Hum Pathol 41: 1516-1529, 2010.
34. Silva IA, Bai S, McLean K, et al: Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res 71: 3991-4001, 2011.
35. Woo T, Okudela K, Mitsui H, et al: Prognostic value of CD133 expression in stage I lung adenocarcinomas. Int J Clin Exp Pathol 4: 32-42, 2010.
36. Levina V, Marrangoni A, Wang T, et al: Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop. Cancer Res 70: 338-346, 2010.
37. Maheswaran S and Haber DA: Circulating tumor cells: a window into cancer biology and metastasis. Curr Opin Genet Dev 20: 96-99, 2010.
38. Gudemann CJ, Weitz J, Kienle P, et al: Detection of hematogenous micrometastasis in patients with transitional cell carcinoma. J Urol 164: 532-536, 2000. (Pubitemid 30481979)
39. Naito T, Tanaka F, Ono A, et al: Prognostic impact of circulating tumor cells in patients with small cell lung cancer. J Thorac Oncol 7: 512-519, 2012.
40. Guzzo TJ, McNeil BK, Bivalacqua TJ, Elliott DJ, Sokoll LJ and Schoenberg MP: The presence of circulating tumor cells does not predict extravesical disease in bladder cancer patients prior to radical cystectomy. Urol Oncol 30: 44-48, 2012.